Leah Cann
Stock Analyst at Brookline Capital
(2.05)
# 2,904
Out of 4,761 analysts
16
Total ratings
42.86%
Success rate
8.66%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Leah Cann
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MEIP MEI Pharma | Maintains: Buy | $80 | $2.60 | +2,976.92% | 2 | May 23, 2023 | |
| CRBU Caribou Biosciences | Initiates: Buy | $19 | $1.31 | +1,350.38% | 1 | Feb 14, 2022 | |
| CCCC C4 Therapeutics | Initiates: Buy | $54 | $3.01 | +1,694.02% | 1 | Jun 24, 2021 | |
| AGIO Agios Pharmaceuticals | Assumes: Perform | n/a | $35.22 | - | 4 | Feb 20, 2019 | |
| EXEL Exelixis | Upgrades: Outperform | n/a | $36.85 | - | 2 | Feb 27, 2018 | |
| NTLA Intellia Therapeutics | Initiates: Perform | n/a | $12.17 | - | 1 | Jul 18, 2017 | |
| EDIT Editas Medicine | Initiates: Perform | n/a | $1.92 | - | 1 | Jul 18, 2017 | |
| CRSP CRISPR Therapeutics AG | Initiates: Perform | n/a | $47.91 | - | 1 | Jul 18, 2017 | |
| VSTM Verastem | Initiates: Outperform | $72 | $5.68 | +1,167.61% | 3 | Apr 13, 2017 |
MEI Pharma
May 23, 2023
Maintains: Buy
Price Target: $80
Current: $2.60
Upside: +2,976.92%
Caribou Biosciences
Feb 14, 2022
Initiates: Buy
Price Target: $19
Current: $1.31
Upside: +1,350.38%
C4 Therapeutics
Jun 24, 2021
Initiates: Buy
Price Target: $54
Current: $3.01
Upside: +1,694.02%
Agios Pharmaceuticals
Feb 20, 2019
Assumes: Perform
Price Target: n/a
Current: $35.22
Upside: -
Exelixis
Feb 27, 2018
Upgrades: Outperform
Price Target: n/a
Current: $36.85
Upside: -
Intellia Therapeutics
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $12.17
Upside: -
Editas Medicine
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $1.92
Upside: -
CRISPR Therapeutics AG
Jul 18, 2017
Initiates: Perform
Price Target: n/a
Current: $47.91
Upside: -
Verastem
Apr 13, 2017
Initiates: Outperform
Price Target: $72
Current: $5.68
Upside: +1,167.61%